Dr. Zeldis has served as a member of our Board since September 2012. Dr. Zeldis served as the Executive Vice President and Head of Research and Development of NexImmune, Inc., a Nasdaq-listed clinical-stage biotechnology company from January 2021 to March 2023. From August 2016 through March 2020, Dr. Zeldis served as the Chief Medical Officer of Sorrento Therapeutics, Inc., a public clinical stage biopharmaceutical company. From August 2017 through September 2018, Dr. Zeldis served as the Chief Medical Officer of Celularity, Inc., a biotechnology company. Prior to joining Sorrento, Dr. Zeldis served as Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he had been employed since 1997. He previously served as Celgene’s Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School, Rutgers University. Dr. Zeldis received an A.B. and M.S. from Brown University and a M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. Dr. Zeldis has served on the board of directors of Soligenix, Inc., a Nasdaq-listed biopharmaceutical company, since 2011; NexGel, Inc., a Nasdaq-listed company, since 2020; and has previously served on the board of directors of several public companies including; BioSig Technologies, Inc., a Nasdaq-listed diagnostic company, from 2015 to 2017 and from 2019 to 2020; Alliqua BioMedical, Inc., a Nasdaq-listed biomedical company, from 2011 to 2017; MetaStat, Inc., a medical device company traded on the OTCQB, from 2016 to 2019; and Kalytera Therapeutics, Inc., a pharmaceutical company traded on the TSXV, from 2015 to 2017.
What is Jerome B. Zeldis' net worth?
The estimated net worth of Jerome B. Zeldis is at least $797,572.50 as of December 2nd, 2024. Dr. Zeldis owns 14,500 shares of PTC Therapeutics stock worth more than $797,573 as of March 26th. This net worth estimate does not reflect any other assets that Dr. Zeldis may own. Learn More about Jerome B. Zeldis' net worth.
How do I contact Jerome B. Zeldis?
The corporate mailing address for Dr. Zeldis and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at ehill@ptcbio.com. Learn More on Jerome B. Zeldis' contact information.
Has Jerome B. Zeldis been buying or selling shares of PTC Therapeutics?
Jerome B. Zeldis has not been actively trading shares of PTC Therapeutics in the last ninety days. Most recently, Jerome B. Zeldis sold 24,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $51.50, for a transaction totalling $1,236,000.00. Following the completion of the sale, the director now directly owns 14,500 shares of the company's stock, valued at $746,750. Learn More on Jerome B. Zeldis' trading history.
Who are PTC Therapeutics' active insiders?
PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Lee Golden (Chief Medical Officer), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?
During the last twelve months, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 267,459 shares worth more than $13,390,759.53. The most recent insider tranaction occured on March, 13th when Director Stephanie Okey sold 5,000 shares worth more than $270,000.00. Insiders at PTC Therapeutics own 5.5% of the company.
Learn More about insider trades at PTC Therapeutics. Information on this page was last updated on 3/13/2025.
